Biodexa Pharmaceuticals (BDRX) Non-Current Debt (2013 - 2025)
Biodexa Pharmaceuticals (BDRX) posted Non-Current Debt of $16.6 million for Q4 2025, up 2376.41% sequentially from $668356.9 in Q2 2025, and up 46.37% YoY from $11.3 million in Q4 2024.
Biodexa Pharmaceuticals (BDRX) Non-Current Debt (2013 - 2025) Analysis & Trends
Biodexa Pharmaceuticals has reported Non-Current Debt for 13 years, with the latest figure at $16.6 million in Q4 2025.
- Quarterly Non-Current Debt rose 46.37% year-over-year to $16.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $16.6 million (up 46.37% YoY) and the FY2025 annual result came in at $16.4 million, up 45.09% from the prior year.
- Non-Current Debt climbed to $16.6 million in Q4 2025 per BDRX's latest filing, from $668356.9 in the prior quarter.
- Over five years, Non-Current Debt peaked at $16.6 million in Q4 2025 and troughed at $262541.9 in Q2 2024.
- A 5-year average of $8.0 million and a median of $9.3 million in 2021 frame the typical range for Non-Current Debt.
- The sharpest annual moves came in 2023 and 2025: Non-Current Debt slumped 95.65% in 2023, then jumped 154.57% in 2025.
- Over 5 years, Non-Current Debt stood at $15.9 million in 2021, then tumbled by 65.32% to $5.5 million in 2022, then jumped by 58.68% to $8.7 million in 2023, then increased by 29.6% to $11.3 million in 2024, then jumped by 46.37% to $16.6 million in 2025.
- According to Business Quant data, Non-Current Debt over the past three periods registered $16.6 million, $668356.9, and $11.3 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | - |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 546.77 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 8.96 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 360.97 Mn |
| 10 | Biodexa Pharmaceuticals | 63,168.17 | -11.29 Mn | - | 16.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 16.55 Mn |
| Jun 30, 2025 | 668,356.89 |
| Dec 31, 2024 | 11.31 Mn |
| Jun 30, 2024 | 262,541.92 |
| Dec 31, 2023 | 8.73 Mn |
| Jun 30, 2023 | 475,518.00 |
| Dec 31, 2022 | 5.50 Mn |
| Jun 30, 2022 | 10.94 Mn |
| Dec 31, 2021 | 15.85 Mn |
| Jun 30, 2021 | 9.82 Mn |
| Dec 31, 2020 | 12.25 Mn |
| Jun 30, 2020 | 12.75 Mn |
| Dec 31, 2019 | 22.06 Mn |
| Jun 30, 2019 | 2.09 Mn |
| Dec 31, 2018 | 19.08 Mn |
| Jun 30, 2018 | 27.91 Mn |
| Dec 31, 2017 | 40.68 Mn |
| Jun 30, 2017 | 42.90 Mn |
| Dec 31, 2016 | 2.01 Mn |
| Jun 30, 2016 | 65.15 Mn |